View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Pall Corporation
27 September 2018

Pall Corporation and G-CON Manufacturing to Deliver Scalable Turnkey PODs®

Prefabricated and prequalified cleanroom solutions provider G-CON Manufacturing is collaborating with Pall Corporation to bring turnkey continuous bioprocess or viral vector production facility solutions to the industry.

G-CON PODs will be customised with advanced Pall Biotech bioprocess equipment, including automation and utility supplies. These will be predesigned into the G-CON cleanroom units for scalable deployment.

Vice-president and general manager at Pall Biotech Mario Philips said: “Together, Pall’s cutting-edge technology and G-CON’s flexible cleanroom platform take the concept of modularity one step further, delivering a complete, reproducible, scalable facility solution that is easy to place or relocate, as well as clean, sanitise and even repurpose.

“This strategic collaboration is particularly important to Pall, as we continuously improve bioprocesses for the industry by offering innovative solutions like G-CON PODs customised with Pall technologies. This solution addresses customer demand for higher efficiencies, while enjoying more flexibility through scale-out and localisation of manufacturing.”

PODs from G-CON are mobile and include integrated process piping and heating and air conditioning (HVAC) systems. Deploying the customised PODs is simple by design, allowing a customer to focus on the target molecule, while relying on the G-CON and Pall teams to optimise the facility design and process.

Once designed, the PODs ease verification, qualification and validation challenges by providing comprehensive site acceptance testing and even Installation Qualification (IQ) / Operational Qualification (OQ) support. The PODs’ flexibility allows them to support multiple products, and they can be easily repurposed. In addition, the cost of building a facility is drastically reduced, as is build time, which increases the return on investment.

President and CEO of G-CON Manufacturing Maik Jornitz said: “G-CON’s prefabricated cleanroom units feature a complete, yet compressed footprint for Pall’s continuous bioprocessing and viral vector production designs. The implementation of the Pall processes in our POD infrastructure creates an ideal turnkey solution for our customers. These solutions will be readily deployable and scalable, as they reduce the typical design, verification and qualification efforts by standardising processes and cleanroom environments.

“We are looking forward to combining our PODs with Pall’s process knowledge and designs to serve our joint customer base. The industry requires optimised, fast, scalable solutions, and these requirements will be met through this collaboration.”

Engineering teams from G-CON and Pall will align to design and deliver the mobile, prefabricated cleanroom units to meet individual customer needs. Process solutions will also be addressed in response to customer needs and applications. Both companies will continue to offer their products and services independently, in addition to the collaboration.

Selecting the right filter integrity test instrument is an important task. An informed, balanced choice will support seamless integration of the instrument into critical processes...
Founded by Dr David B Pall in 1946, Pall Corporation has grown from a company producing filters for the airline industry to a global innovator...
Recent advances in personalised regenerative medicine have been significant. However, further developments are needed to support market and regulatory demands, particularly the development of manufacturing...
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology